BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	chidamide Sensitive: A1 - Approval chidamide Sensitive : A1	chidamide Sensitive: A1 - Approval chidamide Sensitive : A1
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2
BCL2 elevation + IGH elevation	Follicular Lymphoma	BCL2 elevation + IGH elevation	Follicular Lymphoma	rituximab Resistant: B - Late Trials rituximab Resistant : B	rituximab Resistant: B - Late Trials rituximab Resistant : B
MYC overexpression + BCL2 overexpression	Diffuse Large B Cell Lymphoma	MYC overexpression + BCL2 overexpression	Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B
BCL2 overexpression	Multiple Myeloma	BCL2 overexpression	Multiple Myeloma	venetoclax Sensitive: B - Late Trials venetoclax Sensitive : B	venetoclax Sensitive: B - Late Trials venetoclax Sensitive : B
BCL2 overexpression + MYC overexpression	Diffuse Large B Cell Lymphoma	BCL2 overexpression + MYC overexpression	Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B
BCL2 expression	Diffuse Large B Cell Lymphoma	BCL2 expression	Diffuse Large B Cell Lymphoma	venetoclax + obinutuzumab Sensitive: C2 – Inclusion Criteria venetoclax + obinutuzumab Sensitive : C2	venetoclax + obinutuzumab Sensitive: C2 – Inclusion Criteria venetoclax + obinutuzumab Sensitive : C2
BCL2 expression	Acute Myelogenous Leukemia	BCL2 expression	Acute Myelogenous Leukemia	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
BCL2 positive	Diffuse Large B Cell Lymphoma	BCL2 positive	Diffuse Large B Cell Lymphoma	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Lymphoma	MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Lymphoma	lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria lisocabtagene maraleucel Sensitive : C2	lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria lisocabtagene maraleucel Sensitive : C2
BCL2 positive	Estrogen Receptor Positive Breast Cancer	BCL2 positive	Estrogen Receptor Positive Breast Cancer	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
BCL2 expression	Non-Hodgkin’s Lymphoma	BCL2 expression	Non-Hodgkin’s Lymphoma	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
BCL2 expression	Diffuse Large B Cell Lymphoma	BCL2 expression	Diffuse Large B Cell Lymphoma	lenalidomide Sensitive: C2 – Inclusion Criteria lenalidomide Sensitive : C2	lenalidomide Sensitive: C2 – Inclusion Criteria lenalidomide Sensitive : C2
BCL2 rearrangement	Lymphoma	BCL2 rearrangement	Lymphoma	CAR-T immunotherapy Resistant: C3 – Early Trials CAR-T immunotherapy Resistant : C3	CAR-T immunotherapy Resistant: C3 – Early Trials CAR-T immunotherapy Resistant : C3
BCL2 mutation	Follicular Lymphoma	BCL2 mutation	Follicular Lymphoma	nivolumab + ibrutinib Sensitive: C3 – Early Trials nivolumab + ibrutinib Sensitive : C3	nivolumab + ibrutinib Sensitive: C3 – Early Trials nivolumab + ibrutinib Sensitive : C3
BCL2 positive	Diffuse Large B Cell Lymphoma	BCL2 positive	Diffuse Large B Cell Lymphoma	methotrexate Sensitive: C3 – Early Trials methotrexate Sensitive : C3	methotrexate Sensitive: C3 – Early Trials methotrexate Sensitive : C3
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	cytarabine + methotrexate Resistant: C3 – Early Trials cytarabine + methotrexate Resistant : C3	cytarabine + methotrexate Resistant: C3 – Early Trials cytarabine + methotrexate Resistant : C3
BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	methotrexate Resistant: C3 – Early Trials methotrexate Resistant : C3	methotrexate Resistant: C3 – Early Trials methotrexate Resistant : C3
BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	cytarabine + methotrexate Resistant: C3 – Early Trials cytarabine + methotrexate Resistant : C3	cytarabine + methotrexate Resistant: C3 – Early Trials cytarabine + methotrexate Resistant : C3
BCL2 rearrangement	Diffuse Large B Cell Lymphoma	BCL2 rearrangement	Diffuse Large B Cell Lymphoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
BCL2/MCL1 ratio elevation	Acute Myelogenous Leukemia	BCL2/MCL1 ratio elevation	Acute Myelogenous Leukemia	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3
BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
MYC translocation + BCL2 translocation	Diffuse Large B Cell Lymphoma	MYC translocation + BCL2 translocation	Diffuse Large B Cell Lymphoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
BCL2/BCL2L1 ratio elevation	Acute Myelogenous Leukemia	BCL2/BCL2L1 ratio elevation	Acute Myelogenous Leukemia	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3
MYC positive + BCL2 positive	Diffuse Large B Cell Lymphoma	MYC positive + BCL2 positive	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: C3 – Early Trials axicabtagene ciloleucel Sensitive : C3	axicabtagene ciloleucel Sensitive: C3 – Early Trials axicabtagene ciloleucel Sensitive : C3
MYC positive + BCL2 positive + BCL6 positive	Diffuse Large B Cell Lymphoma	MYC positive + BCL2 positive + BCL6 positive	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: C3 – Early Trials axicabtagene ciloleucel Sensitive : C3	axicabtagene ciloleucel Sensitive: C3 – Early Trials axicabtagene ciloleucel Sensitive : C3
BCL2 amplification	Diffuse Large B Cell Lymphoma	BCL2 amplification	Diffuse Large B Cell Lymphoma	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
MYC overexpression + BCL2 overexpression	Diffuse Large B Cell Lymphoma	MYC overexpression + BCL2 overexpression	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: C3 – Early Trials axicabtagene ciloleucel Sensitive : C3	axicabtagene ciloleucel Sensitive: C3 – Early Trials axicabtagene ciloleucel Sensitive : C3
MYC translocation + BCL2 translocation	Non-Hodgkin’s Lymphoma	MYC translocation + BCL2 translocation	Non-Hodgkin’s Lymphoma	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3

BCL2 (B-cell CLL/lymphoma 2)

Associations(138)

Associations
(138)